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1. Introduction
The number of patients treated for end-stage renal failure continuously increases. Because
treatment alternatives are limited and transplants are often the first therapeutic choice, the
numbers of patients joining the waiting lists in countries world-wide rises. At present trans‐
plantation medicine is one of the most progressive fields of medicine. Gradually the “half-life”
of renal transplants improved and the five years survival rate ranges now above 80% [1;2].
Despite of the advances made within the last decades, acute rejection (AR) is still a risk for
graft survival. The incidence of rejection episodes depends on several factors, e.g., the organ
(status), co-morbidities, medication and compliance. Thus, in different situations the incidence
of AR varies between 13-53% in the first year after transplantation [3], and, in most cases,
cellular and humoral immunity mediated rejections can be distinguished. Usually, AR pro‐
ceeds substantially as an acute cellular rejection whereas humoral rejection comprises only a
smaller proportion of AR [4]. Every single episode of an AR is a negative prognostic factor,
increasing the risk for development of chronic allograft deterioration and worsening long-term
graft survival [5;6]. Interestingly, the impact of AR on chronic renal allograft failure as the main
cause for death-censored graft-loss after kidney transplantation increases, whereas the severity
of the episode itself is an independent risk factor [7-9]. Therefore, early detection and rapid
and effective treatment of AR are essential to preserve graft`s function. Clinically established
screening methods such as elevated serum creatinine, occurrence or aggravation of proteinu‐
ria, oliguria, hypertension, graft tenderness, or peripheral edema, often lack the desired sen‐
sitivity and specificity for early diagnoses of AR. Hence,a compelling need for high sensitive
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and specific detection of early AR exists, with core needle biopsy still being the “gold-stand‐
ard” in rejection diagnostics. However, biopsy as an invasive procedure is cumbersome to the
patient, carries the risk of graft injury, and cannot be applied in patients taking anticoagulant
drugs. Additionally, the sampling site is small and one might miss AR, i.e., when rejection is
focal or patchy. Thus, in diagnostics, non-invasive image-based methods visualizing the whole
graft would be superior.
Allograft rejection is the result of interactions between the recipient`s innate and adaptive
immune system and the graft antigens serving as a target. Cytotoxic T lymphocytes (CTLs) are
central effectors within AR whereas B cells and parts of the congenital immunosystem such as
the complement system, monocytes/macrophages, neutrophilic granulocytes, and dendritic
cells, have their share, too [4;10]. By recognition of their donor antigen CTLs are activated,
undergo clonal expansion and differentiation into effector cells. Subsequently, they migrate
into the transplant initiating its destruction [4;10;11]. Before CTLs reach the graft parenchyma,
they have to pass the vascular endothelium. This extravasation is mediated by chemoattractant
cytokines/chemokines. Chemokines induce the expression of vascular adhesion molecules al‐
lowing leukocytes to roll, adhere, and transmigrate into the parenchyma [12]. CTLs destroy
their targets through the release of perforin and granzyme or by initiation of the Fas/FasL
pathway inducing cell death by triggering the inherent caspase-mediated apoptotic response
or caspase-independent cell death [13]. These two cell death-inducing strategies account for
almost all contact-dependent target kills. However, activated CTLs can release additional cy‐
tokines, such as tumor-necrosis factor and interferon causing apoptosis or necrosis upon se‐
cretion [11,13]. Moreover, inflammatory edema and micro thrombi / hemorrhage caused by
damaged endothelium add ischemia-dependent hypoxic damage to the graft [11]. All of these
single, simplified processes sum up and promote allograft dysfunction. However, if they are
characterized at least in part, they can be addressed by different imaging technologies dis‐
cussed in the following.
2. Ultrasound
Standard care in detection of AR includes (Doppler-) ultrasound examination. Typical ultra‐
sound findings in cases of AR are rejection-related graft enlargement (swelling, more globular
shape), reduction of corticomedullary differentiation, increased echogenicity, prominent me‐
dullary pyramids, or irregularities in the graft perfusion (reversed plateau of diastolic flow),
but its specificity and sensitivity for AR is limited, even when echo enhancers are applied
[14;15]. Elevated resistance indices can occur in the presence of acute as well as chronic rejec‐
tion. However, values lower than 0.8 are expected and usually values above 0.8 indicate in‐
creased intrarenal pressure as it occurs for example in acute tubular necrosis (ATN) or AR and
is linked to a poor longterm renal allograft function [16-18]. Notably, sensitivity and reliability
of this method mainly depend on the investigators experience. A comprehensive overview of
“What ultrasound can do and cannot do” in diagnostics of renal transplant pathologies was
published by Cosgrove and Chan [16]. Using contrast agent or targeted ultrasound in the
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future, this method might offer significant potential, whereas at present studies are at best at
experimental stage and are completely lacking in patients with renal AR.
3. Computed tomography
Computed tomography (CT) is commonly available, technology and techniques as well as the
applied contrast media constantly improve. CT contrast agents allow accurate evaluation of
parenchymal, perirenal, renal sinus, pyeloureteral and vascular diseases in renal transplanta‐
tion in great detail and at lower costs than by magnetic resonance (MR) imaging. Information
gathered by CT indicating AR are loss of corticomedullary differentiation, decreased graft
enhancement, and delayed or absent contrast excretion [19]. However, this information is
rather unspecific and the contrast media used still are nephrotoxic. Thus, at present CT has no
role in diagnostics of renal AR.
4. Magnetic resonance imaging
Kalb et al. provide a recent overview about MR-based approaches for functional and structural
evaluations of renal grafts including a section on diagnostics of AR [20]. Beside exact anatom‐
ical information, MR can assess different aspects of renal function. Typical MR findings oc‐
curring in AR are enlargement of the graft (due to edema) with loss of corticomedullary
differentiation and elevated cortical relative signal. There might be edema of and surrounding
the kidney and the ureter. The high spatial and temporal resolution of MR allows perfusion
imaging which might be useful to distinguish AR from ATN. 3D gradient echo perfusion
imaging might show enhancement of the cortex and markedly delayed excretion of contrast
[20]. Recent research with blood-oxygen level-dependent (BOLD) MR was promising for dif‐
ferentiating AR from ATN and a normal functioning kidney [21,22]. Furthermore, MR renog‐
raphy has been applied for diagnosis of the cause of acute dysfunction after kidney
transplantation [23,24]. These two studies rely on quantitative evaluation of the shape of the
renal enhancement curve to diagnose acute dysfunction. One can observe delayed and lower
medullary enhancement in ATN whereas cortical and medullary enhancement curves de‐
crease in AR. However, further studies verifying the results are needed and still some issues
about gadolinium-containing contrast agents and nephrogenic systemic fibrosis and gadoli‐
nium nephrotoxicity need to be resolved. More recently, Yamamoto et al. proposed a new
quantitative analysis method of MR renography, including a multicompartmental tracer ki‐
netic renal model for diagnosis of AR and ATN, but state in their paper that findings in patients
with normal graft function, AR, and ATN showed a substantial overlap with those of the
normal population [25]. Another strategy followed was imaging of macrophage infiltration
with ultrasmall superparamagnetic iron oxide particles [26]. Grafts with AR showed signifi‐
cant accumulation of iron particles but only within a time frame of 72 h which is much too late
for potential clinical application.
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5. Single photon (gamma) imaging and positron emission tomography
Because gamma camera/ single photon emission computer tomography (SPECT) and positron
emission tomography (PET) offer high intrinsic activity, excellent tissue penetration (depend‐
ing on the tracer), cover the whole organ/ body, are relatively independent of the experience
of the investigator and provide a huge variety of clinically tested molecular imaging agents/
tracer, SPECT and PET-based approaches for the detection of renal AR are discussed in the
following [27;28]. Steps of AR addressed by SPECT or PET-based approaches include recruit‐
ment of activated leukocytes into the transplant with consecutive cytokine release, cell death,
edema, hypoxia and loss of function.
A comprehensive overview of the studies performed is provided in Table 1.
SPECT
Target Molecular Marker Graft/Organ Species References
Fibrin thrombi 99mTc-Sulfur Colloid Kidney Human, dog [64;65]
Proximal tubule uptake 99mTc-DMSA Kidney Human [66;67]
Renal uptake and excretion 99mTc-MAG3 Kidney Human [68]
Renal perfusion and filtration 99mTc-pentetate (DTPA) Kidney Human [69;70]
Leukocytes 99mTc-OKT3 Kidney Human [40]
Inflammation 99mTc- Leukocytes Kidney Human [39]
67Ga citrate Kidney Human [64;65]
Renal function 131I-OIH Kidney Human [71]
PET
Metabolism/Inflammation 18F-FDG Kidney Rat [43;44]
Leukocytes 18F-FDG-Leukocytes Kidney Rat In press
A Medline literature search by PubMed was performed to select papers in which AR and SPECT/PET play any role. The
search period was set from 1970 to July 2012. We used ("Acute renal or kidney rejection" and "positron emission to‐
mography (PET)" or "single photon gamma imaging (SPECT)" or "molecular imaging") as search query. Only papers with
an English abstract have been included.
Table 1. Results of literature analysis: SPECT/PET-based diagnosis of renal AR.
5.1. Inflammation
Sterile inflammation is central to the rejection process. Hence, it seems logically to assess in‐
flammatory targets for the diagnosis of AR. In inflammation imaging, one can focus on target
mechanisms such as measurement of the metabolic activity (i.e. with the “classical” tracer 18F-
fluordesoxyglucose (FDG)), binding to cytokines/chemokines (receptors), assessment of phys‐
ically trapped tracers in the inflammatory edema, or using leukocytes. Recently, Signore et
Current Issues and Future Direction in Kidney Transplantation92
al. published an excellent review on imaging of inflammation discussing different techniques,
targets, and approaches [27].
5.2. Vascular adhesion molecules
AR is associated with the expression of cell adhesion molecules like vascular cell adhesion
molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), carcinoembryonic antigen-
related cell adhesion molecule 1 (CEACAM1), LFA-1 (lymphocyte function-associated anti‐
gen-1, and endothelial leukocyte adhesion molecule (E-selectin) on the endothelium of organs
undergoing rejection. They are “essentially needed” for the adherence and transmigration of
leukocytes into the parenchyma. Because radiolabeled antibodies exist for some of these easily
accessible vascular targets, they can be addressed by noninvasive imaging. However, data
regarding adhesion markers in SPECT/PET-based imaging are rare and have not been trans‐
ferred to renal AR imaging yet.
5.3. Imaging using ex vivo radiolabeled leukocytes
Because recruitment and activation of inflammatory cells, i.e. lymphocytes, is crucial to AR,
efforts have been made to image infiltration by means of labeled leukocytes. Application of
ex vivo radiolabeled leukocytes is clinically well established particularly in the diagnostic
workup of infectious disorders without a focus. Hitherto, white blood cells (WBC) are labeled
using for instance 99mTc-HMPAO or 111In-oxine for SPECT and 18F-FDG or 64Cu for PET analysis,
respectively [29]. These cells are considered to accumulate highly specific in inflamed tissues
[30-33].
After injection of labeled leukocytes a typical distribution pattern can be observed. First, cells
shortly accumulate in the lungs and then continuously migrate from the blood pool into spleen,
liver, and bonemarrow, the so called reticulo-endothelial system, and certainly in inflamed
sites [34-36]. After endothelial adhesion, labeled leukocytes migrate through the vessel`s wall
to the focus of inflammation providing a typical radioactivity pattern indicating infiltration.
For instance, Forstrom et al. have shown that 18F-FDG labeled leukocytes exhibit comparable
distribution patterns in normal human subjects compared with 111In or 99mTc-labeled WBC [37].
Although 18F-FDG seems to exhibit the lowest labeling stability when compared to 111In and
64Cu only neglectible free 18F-FDG uptake can be observed [37]. However, labeling stability is
relevant in order to assure that assessed activity refers to accumulation of labeled leukocytes
and not to the unlabeled tracer only. Since half-life time of 18F-FDG is 109 min, longtime stability
of 18F-FDG labeled leukocytes for clinical analysis is not of interest. However, if longtime sta‐
bility is of interest this could be addressed using other tracers like 99mTc with a half life of
approximately 66h.
Successful imaging using labeled leukocytes depends on viability of labeled cells. Several
studies assessed cell viability after labeling concluding satisfactory and comparable viability
rates for 111In, 99mTc, 18F-FDG and 64Cu in the first 4h after labeling [38]. However, cell viability
significantly decreases within one day limiting long term monitoring of AR using a single shot
approach.
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At present only a few preclinical and clinical studies are published dealing with labeled leu‐
kocytes and detection of AR in intestine, hearts, pancreas islets and skin. Only one study per‐
formed in a small cohort of kidney transplant recipients evaluated 99mTc-mononuclear cell
scintigraphy for diagnosis of AR. In this study, the authors were able to show that AR was
diagnosed correctly and successfully discriminated from ATN [39]. In a further development
of their approach, we established leukocyte PET imaging using very low amounts of 18F-FDG
for the diagnosis of AR in a rat kidney transplant model. Ex vivo 18F-FDG labeled human CTLs
were able to diagnose renal AR within a time frame of 1 h after application and discriminate
AR from important differential diagnoses such as acute cyclosporine toxicity or ATN (Grabner
et al. in press) (Fig. 1).
Figure 1. Representative PET-images of dynamic whole body acquisitions of a series of an allogeneically kidney trans‐
planted rat on postoperative day 4 60 min and 120 min after tail vein injection of 30 x 10618F-FDG labeled CTL. While
the parenchyma (yellow circle) of renal allograft developing AR accumulates 18F-FDG-CTLs, the native kidney (green
circle) does not show any accumulation at any time. Please note that the renal pelvis can contain eliminated 18F-FDG/
18F-fluoride. Therefore, it has to be excluded from the measurements. ID: injected dose
Since infiltration of leukocytes, especially CTLs, in allografts appears before physiologic or
mechanical manifestations of organ dysfunction is apparent, nuclear imaging employing leu‐
kocytes might be a promising tool for specific, sensitive and early detection of AR.
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5.4. Imaging using in vivo radiolabeled leukocytes
Instead of employing ex vivo labeled leukocytes, radiolabeled monoclonal antibodies (frag‐
ments) (mAbs) have been established for detection of leukocyte (related) antigens. Their ad‐
vantages include standardized production, easier storage and handling, while they are highly
specific for their target leading to a good background/target ration. However, limitations might
be the targeting of extravascular antigens and potential but rare allergic complications, when
using the antibodies in a patient.
As discussed, CTLs are the major cell type involved in AR. Martins et al. used 99mTc-OKT3
targeting CTLs in recipients of renal transplants [40]. In their preliminary results they state
that out of 22 patients they successfully identified 3 patients with AR using 99mTc-OKT3 scans.
Apparently, their results published in 2004 have to be confirmed in further studies. A recently
published attractive, being somehow better biocompatible, alternative might be CD3 targeting
99mTc-SHNH-visilizumab which needs to be evaluated in the future [41].
5.5. Metabolic activity (18F-FDG)
18F-FDG is a daily routine tracer to assess regional glucose metabolism as a surrogate for met‐
abolic activity widely used for the PET-based routine detection of tumors, infection and in‐
flammation. The major energy source in leukocytes during the metabolic burst is glucose.
Analogously, activated leukocytes highly accumulate 18F-FDG (in the same way they take up
glucose but without further processing) which can be quantified by PET [42]. A clear limitation
when using free 18F-FDG is that an increased uptake can be observed in any kind of cellular
activation (high glycolytic activity). Hence, 18F-FDG is not a disease or target specific tracer.
Nevertheless, 18F-FDG is one of the few tracers successfully applied for the non-invasive de‐
tection of AR. Others have applied 18F-FDG in settings of lung, heart and liver transplantations.
We have demonstrated very promising results for 18F-FDG-PET in diagnostics of renal AR
[43;44]. Using a rat model of renal AR, 18F-FDG-PET performed well in terms of early, accurate
detection and follow-up of AR [43] (Fig. 2). Using 18F-FDG, we discriminated AR non-inva‐
sively from important differential diagnoses like ATN or acute cyclosporine toxicity. More‐
over, therapy response monitoring by 18F-FDG might be useful to identify treatment
unresponsive AR for earlier escalation of immunosuppressive regimen [44]. This might reduce
graft damage by shortening AR episodes because at present (steroid) resistant rejection is di‐
agnosed lately [45].
One important issue of imaging of kidney AR with 18F-FDG is that it is eliminated with the
urine in contrast to normal glucose. Thus, drainage of 18F-FDG into the renal pelvis must be
taken care of when assessing 18F-FDG-uptake in the renal parenchyma. We avoided this prob‐
lem by using late acquisitions after 18F-FDG injection to reduce the instantaneous amount of
tracer in the urine during the PET scan. Moreover, an impact of renal function on 18F-FDG-
uptake has to be excluded e.g. by renal fluoride clearance (a non-invasive measure of renal
function) [46].
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Figure 2. Representative PET-images of dynamic whole body acquisitions of a series of an allogeneically kidney trans‐
planted rat (POD 1 (A), 2 (B), 4 (C), and 7 (D), after tail vein injection of 18F-FDG. While the parenchyma (yellow circle)
of renal allograft developing AR accumulates 18F-FDG with a maximum on post operative day (POD) 4, the native kid‐
ney (green circle) does not show any accumulation at any time. Please note that the renal pelvis can contain eliminat‐
ed 18F-FDG/18F-fluoride. Therefore, it has to be excluded from the measurements. Figure taken from [43]. Scale bar:
percent injected dose
5.6. Matrix metalloproteinases
One step further, one cannot assess infiltrating leukocytes only but rather their tissue damag‐
ing activity by detection of activated matrix metalloproteinases (MMPs). Leukocyte-derived
MMPs, like MMP-2 or MMP-9, were found to be active in AR [47;48]. Since MMP activity can
be assessed using radiolabeled MMP-inhibitors in SPECT or PET this approach for detection
of AR might be evaluated in future studies [49-52]. Maybe one can gather additional informa‐
tion regarding graft`s prognosis because MMPs are involved in tissue remodelling, too.
5.7. Hypoxia
Acute tissue inflammations regardless of their origin present with a unique and challenging
microenvironment including hypoxia (low oxygen), anoxia (complete lack of oxygen), hypo‐
glycemia (low blood glucose), acidosis (high H+ concentration) and abundant free oxygen rad‐
icals. These conditions are characteristic features of inflamed tissues, along with the influx of
leukocytes. In renal allografts, hypoxia and hypoxic adaptation are common within 2 weeks
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after surgery whereas graft hypoxia assessed in the long run is associated with clinical/subclin‐
ical rejection [53]. Therefore, assessment of hypoxia by targeting hypoxia (related gene prod‐
ucts), i.e. hypoxia inducible factors (HIF), might offer additional diagnostic information in
subclinical or ambiguous cases of AR.
Two major classes of hypoxia tracer, nitroimidazoles and bis(thiosemicarbazonato)copper(II)
complexes, have been extensively investigated for measuring hypoxia. The applications of
both tracer as well as several alternative reagents tested e.g., 18F-fluoroerythronitroimidazole
(18F-FETNIM) and 18F-fluoroazomycin-arabinofuranoside (18F-FAZA), are summarized in a
review recently published by Krohn et al. [54]. Until present and to the best of our knowledge,
no study has been performed assessing hypoxia in renal AR by SPECT or PET so far. At least
one has to evaluate if the SPECT and PET-based approaches are advantageous when compared
to BOLD MR.
5.8. Apoptosis
Apoptosis in AR is probably the result of different events occurring in AR. It may be a direct
consequence of different cytokines discharged by leukocytes or directly provoked e.g. by CTLs.
Within the inflammatory milieu of AR apoptosis might, among other factors, also be related
to hypoxia, acidosis, or reactive oxygen species. Non-invasive detection of apoptosis in AR
might be attractive because it may not serve for early detection of AR only, but also for mon‐
itoring of rejection kinetics and therapy response. Especially, early assessment of therapeutic
success or failure is interesting to promptly adjust the therapeutic regimen. Likewise, quanti‐
fication of apoptosis might provide information regarding the extent of graft damage and
therefore for its prognosis. However, small studies with different tracers targeting different
steps in apoptosis have been performed in both, animal and man. A comprehensive review on
detecting cell death in vivo has been recently published by us [55]. Two main operational strat‐
egies are followed. While imaging of caspases` activity using substrate-derived agents offers
high selectivity, the detection of membrane phospholipid redistribution using extracellular
agents has the advantage of high target density and accessibility [56]. We and others recently
proposed different isatin analogues for 18F-labeling and detection of apoptosis [55]. However,
studies detecting apoptosis in renal grafts using radiotracers for evaluation of their potential
clinical value in AR have not been performed yet.
5.9. Imaging allograft function
A rather unspecific but reasonable approach is to simply determine graft function as a surro‐
gate for stable function or (acute) graft affection.
Especially scintigraphic methods have been established for the assessment of renal function.
Primarily, two types of imaging are common: static and dynamic. 99mTc-dimercaptosuccinic
acid (DMSA) is the tracer used in static imaging allowing on the one hand identification of
pathological conditions such as anatomical abnormalities or scarring, on the other hand accu‐
rate assessment of the differential function of the kidneys [57]. DMSA uptake correlates with
the effective renal plasma flow, glomerular filtration rate, and creatinine clearance. Therefore,
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DMSA has been successfully applied in the evaluation of renal function in living donors (before
and after transplantation) and in kidney recipients [58]. For dynamic imaging 99mTc-mercap‐
toacetyltriglycine (MAG-3) and diethylenetriaminepentaacetic acid (DTPA) are the most com‐
monly used tracers, whereas MAG-3 is going to replace DTPA because of superior extraction
efficiency. It was proposed that MAG-3 scintigraphy can be useful for discrimination of AR
from ATN [59]. Despite a reasonable perfusion and tracer extraction in ATN as assessed in
these studies, tracer excretion rate is low, whereas one of the typical findings in AR is impaired
perfusion. This fact was already taken into account by Hilson et al. in the seventies who de‐
veloped a DTPA-based perfusion index which allows separation of rejection from ATN and,
particularly, rejection from healthy kidneys [60]. These findings are somehow discrepant to
typical findings in ultrasound when assessing RI which reflects renal perfusion as well. High
RIs can be observed in ATN as well as in AR denying a differentiation of these entities by
ultrasound-based measure of renal perfusion. Potentially, the modified renal perfusion index
using 18F-fluoride developed by us can be used for further clarification [61]. Aside from this
recent studies using PET for the evaluation of renal function other approaches have been
emerged. Renal blood flow for instance was successfully measured with H215O in rats and man
[62,63]. Furthermore, we established 18F-fluoride clearance for assessment of renal function in
different renal failure models including AR [43,46]. As said before, decreased renal function
is not disease specific but can assist in the differential diagnoses of AR.
6. Conclusion
The diagnosis and therapy follow-up of AR in transplant recipients demands for non-invasive
and serial imaging approaches in vivo. Molecular and cellular imaging has significant potential
for transplantation medicine as it may serve for monitoring the graft. With more optimal trac‐
ers as they are numerously being developed, PET (and other devices) may serve as valuable
tools for the diagnosis and management of renal AR. In this term, these techniques will find
their share to impact on detection of AR, graft function, assessment of therapy response as well
as of the progression of lesions and therefore on graft´s prognosis.
Taken the new developments in molecular imaging into account, non-invasive methods in‐
cluding ultrasound, magnetic resonance, as well as SPECT and PET get increasingly helpful
for research. Currently, nearly all of these promising new approaches are still at an experi‐
mental stage and have to evidence their potential in humans in daily routine in the future.
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